This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): OX-MPI
Description: OX-MPI is derived from an entirely new mechanism based on the identification of a specific enzyme – membrane-bound prostaglandin (PG) E synthase (mPGES). This enzyme is necessary for the production of PGE2, a substance produced by the body which plays a pivotal role in many inflammatory processes.
Orexo and Boehringer Ingelheim
In November 2005, an exclusive collaboration and license agreement for the development and commercialization of OX-MPI was signed with Boehringer Ingelheim.
Partners: Orexo AB
Additional information available to subscribers only: